Biotech pharma

Dropprint Genomics

Website

Who we are? We write software that understands the activity of individual cells as opposed to all cells. This approach is novel because we are no longer looking at average signals and can be precise. It is like a police person trying to identify the speeding car, they won’t find it if they look at all the cars at once, rather they need to look at

Overview

Who we are?

We write software that understands the activity of individual cells as opposed to all cells. This approach is novel because we are no longer looking at average signals and can be precise. It is like a police person trying to identify the speeding car, they won’t find it if they look at all the cars at once, rather they need to look at the speed of each individual car. This is the beauty of single cell genomics, we can now identify that speeding car.

Why now?

The biggest barrier for entry into the single cell genomics market are cost and data analysis. To that end, we have reduced the cost by 10-fold and built the computational infrastructure for scalability. Although single cell sequencing has only been around for about five years, we come from one of the top single cell genomics labs and were the first to process and analyze millions of immune cells. Thanks to our software solutions, we have been able to bring big data solutions to the immune system.

Where are we and where are we going?

We have generated a database of over 1 million immune cells spanning healthy, cancerous, and autoimmune immune cells and are growing through paid partnerships. Harnessing out database and ML software, we can take a data-centric approach for better target discovery. Fortunately, as our database continues to grow, our models will continue to learn for more precise, unbiased, and automated single cell genomics.

Thank you!

Company description As recorded 2026-11-08

Founders & team

Rachel Gate

Founder

PhD bioinformatics (UCSF) | Cofounder of Dropprint Genomics (W20; acquired by Immunai) | Currently building out new businesses lines in biotech

Founder profile As recorded 2026-09-15
2team members reported
Source-reported As recorded 2026-09-15

News & product activity

Sources & observations

Y Combinator

Profile depthenriched profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA
Pricing evidenceA pricing page was detected
Maturity: Not assessed · 4 of 6 areas documented

Source-based assessment · automated evidence rules

The source reports an inactive or acquired company; current product identity needs review.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplepricing page observed